First-pass extracted concept

pre-existing anti-AAV immunity

Candidate: concept label1 source documents4 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

However, pre-existing immunity, especially in the form of neutralizing antibodies (NAbs) remains a significant barrier, reducing vector efficacy and restricting patient eligibility.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1barriersupports2025Source 1DOI PubMed

Pre-existing anti-AAV immunity, especially neutralizing antibodies, is a significant barrier to AAV gene therapy because it reduces vector efficacy and restricts patient eligibility.

Claim 2mechanismsupports2025Source 1DOI PubMed

Immune detection and clearance of AAV vectors involve innate pattern recognition receptors, complement activation, and adaptive effector functions including antibody-dependent complement deposition, cytotoxicity, and phagocytosis.

Claim 3mitigation strategysupports2025Source 1DOI PubMed

The review proposes a three-pronged mitigation framework for pre-existing anti-AAV immunity consisting of immune-focused, delivery-focused, and capsid-focused strategies.

Claim 4modulatorsupports2025Source 1DOI PubMed

Species, age, serotype, administration route, and target tissue contribute to immune susceptibility and variable AAV transduction outcomes.